Table 4.
Stratified multivariate analysis
| Adjusted variables |
Adjusted OR (95%CI) |
||
| All cohort (n = 351) | Female (n = 185) | Male (n = 166) | |
| Age at Thiopurine prescription > 40 (sex-by-age interaction, P = 0.04) | 2.4 (1.4-4.2) | 2.8 (1.4-5.6) | 0.9 (0.4-2.1) |
| Female vs male (referent) | 1.2 (0.7-2.0) | NA | NA |
| Smoking history (current/past) | 1.5 (0.9-2.5) | 1.5 (0.8-3.1) | 1.6 (0.8-3.6) |
| Pre-thiopurine intestinal resection vs no resection (referent) | 0.86 (0.43-1.71) | 0.7 (0.3-1.8) | 1.0 (0.4-2.8) |
| L1 vs L2 (referent) | 1.4 (0.6-3.2) | 1.2 (0.4-3.6) | 3.1 (0.9-10.4) |
| L3 vs L2 (referent) | 1.5 (0.7-3.0) | 1.1 (0.4-2.7) | 2.1 (0.7-6.3) |
| B2 vs B1 (referent) | 1 (0.5-2.2) | 1.0 (0.3-2.8) | 0.7 (0.2-2.4) |
| B3 vs B1 (referent) | 1.1 (0.5-2.5) | 1.0 (0.3-2.8) | 0.8 (0.3-2.5) |
| Pre-thiopurine perianal disease vs no perianal disease (referent) | 0.7 (0.4-1.3) | 1.1 (0.5-2.7) | 0.7 (0.3-1.8) |
| 5-ASA at time of thiopurine vs past or never (referent) | 0.8 (0.4-1.5) | 0.7 (0.3-1.8) | 1.0 (0.4-2.4) |
| Corticosteroid at diagnosis vs no exposure at diagnosis (referent) | 0.9 (0.5-1.6) | 0.7 (0.3-1.5) | 0.9 (0.4-2.2) |
| L4 vs L2 (referent) | 1.8 (0.7-4.3) | 3.4 (0.9-12.2) | 0.9 (0.3-3.1) |
Predictors of thiopurine discontinuation in all cohort and as determined by this stratified multivariate analysis by sex. Demographic data suggests a higher incidence of adverse events in female patients over the age of 40 years. An age-by-gender interaction is seen as described in this multivariate analysis of thiopurine-exposed patients in female subjects over the age of 40 years. ASA: Aminosalicylic acid; NA: Not available.